Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dendritic cells (DC) are an essential link between the innate and adaptive immune response. To become effective antigen-presenting cells DC need to undergo maturation, during which they up-regulate co-stimulatory molecules and produce cytokines. There is great interest in utilizing DC in vaccination regimes. Over recent years, Toll-like receptor (TLR) signalling has been recognized to be one of the major inducers of DC maturation. This study describes a mutant version of the TLR adaptor molecule MyD88 (termed MyD88lpr) as a novel adjuvant for vaccination regimes. MyD88lpr specifically activates DC by disrupting a DC intrinsic inhibitory mechanism, which is dependent on single immunoglobulin IL-1R-related. Moreover, MyD88lpr was able to induce an IgG2a-dominated response to a co-expressed antigen, suggesting Th1 immunity. However, when used as a vaccine adjuvant for Influenza nucleoprotein there was no significant difference in the lung viral titres during the infection. This study describes MyD88lpr as a potential adjuvant for vaccinations, which would be able to target DC specifically.

Original publication

DOI

10.1111/j.1365-3083.2010.02392.x

Type

Journal article

Journal

Scandinavian journal of immunology

Publication Date

06/2010

Volume

71

Pages

393 - 402

Addresses

Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, Hammersmith, London, UK.

Keywords

Dendritic Cells, Th1 Cells, Animals, Mice, Inbred BALB C, Mice, Knockout, Humans, Mice, Influenza A virus, Receptors, Interleukin-1, Influenza Vaccines, Adjuvants, Immunologic, Antibodies, Viral, Vaccination, Specific Pathogen-Free Organisms, Female, Influenza, Human, Myeloid Differentiation Factor 88, Immunity, Innate